Scilex Holding, a biopharmaceutical company, agred to go public via a SPAC merger with Vickers Vantage I, a blank cheque company, in a $1.64bn deal. "We are thrilled to have the opportunity to partner with the team at Scilex. We believe Scilex is a uniquely compelling company with excellent non-opioid pain management therapies, which we expect may become cornerstone therapies for treating many acute and chronic pain conditions worldwide," Jeffrey Chi, VCKA Chairman and CEO.